KR20210080373A - Bet 브로모도메인 억제제의 고체 형태를 제조하는 방법 - Google Patents
Bet 브로모도메인 억제제의 고체 형태를 제조하는 방법 Download PDFInfo
- Publication number
- KR20210080373A KR20210080373A KR1020217010933A KR20217010933A KR20210080373A KR 20210080373 A KR20210080373 A KR 20210080373A KR 1020217010933 A KR1020217010933 A KR 1020217010933A KR 20217010933 A KR20217010933 A KR 20217010933A KR 20210080373 A KR20210080373 A KR 20210080373A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- degrees
- cancer
- solid form
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
- B01J23/44—Palladium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730849P | 2018-09-13 | 2018-09-13 | |
| US62/730,849 | 2018-09-13 | ||
| PCT/IB2019/001011 WO2020053657A1 (en) | 2018-09-13 | 2019-09-13 | Method of manufacturing a solid form of a bet bromodomain inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210080373A true KR20210080373A (ko) | 2021-06-30 |
Family
ID=69777480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217010933A Pending KR20210080373A (ko) | 2018-09-13 | 2019-09-13 | Bet 브로모도메인 억제제의 고체 형태를 제조하는 방법 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12145932B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3849980B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7731794B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210080373A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112955449B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019338059B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3111527A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202190598A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3034982T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL281258B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021002885A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202102497SA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI882964B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020053657A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230081602A (ko) * | 2021-11-30 | 2023-06-07 | 주식회사 베노바이오 | Bet 단백질을 저해하는 신규한 카르복스아마이드 리독스 유도체 및 이를 이용한 안과질환 예방 및 치료용 조성물 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI882964B (zh) | 2018-09-13 | 2025-05-11 | 大陸商恒翼生物醫藥(上海)股份有限公司 | Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法 |
| TW202327594A (zh) | 2021-09-23 | 2023-07-16 | 大陸商恒翼生物醫藥(上海)股份有限公司 | 用bet溴結構域抑制劑和parp抑制劑的組合治療預選患者群體的三陰性乳腺癌的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| CN105473581B (zh) | 2013-06-21 | 2019-04-23 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的新取代的双环化合物 |
| KR102307566B1 (ko) * | 2013-06-21 | 2021-10-05 | 제니쓰 에피제네틱스 리미티드 | 신규한 바이사이클릭 브로모도메인 억제제 |
| BR122019007990B1 (pt) | 2013-11-18 | 2021-05-04 | Forma Therapeutics, Inc | Composto, e, composição farmacêutica |
| CA2966452A1 (en) | 2014-12-17 | 2016-06-23 | Samuel David Brown | Substituted bicyclic compounds as bromodomain inhibitors |
| WO2017075377A1 (en) * | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| CN109715625B (zh) * | 2016-06-20 | 2022-04-19 | 因赛特公司 | Bet抑制剂的结晶固体形式 |
| WO2018097977A1 (en) | 2016-11-22 | 2018-05-31 | Gilead Sciences, Inc. | Crystalline forms of a phosphate complex of a bet inhibitor |
| TWI816880B (zh) | 2018-09-13 | 2023-10-01 | 大陸商恒翼生物醫藥(上海)股份有限公司 | 治療前列腺癌之組合療法 |
| TWI841598B (zh) | 2018-09-13 | 2024-05-11 | 大陸商恒翼生物醫藥(上海)股份有限公司 | 用於治療雌激素受體陽性乳癌之組合療法 |
| TWI882964B (zh) | 2018-09-13 | 2025-05-11 | 大陸商恒翼生物醫藥(上海)股份有限公司 | Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法 |
-
2019
- 2019-09-12 TW TW108133099A patent/TWI882964B/zh active
- 2019-09-13 EA EA202190598A patent/EA202190598A1/ru unknown
- 2019-09-13 ES ES19860308T patent/ES3034982T3/es active Active
- 2019-09-13 CA CA3111527A patent/CA3111527A1/en active Pending
- 2019-09-13 WO PCT/IB2019/001011 patent/WO2020053657A1/en not_active Ceased
- 2019-09-13 KR KR1020217010933A patent/KR20210080373A/ko active Pending
- 2019-09-13 US US17/275,465 patent/US12145932B2/en active Active
- 2019-09-13 IL IL281258A patent/IL281258B2/en unknown
- 2019-09-13 EP EP19860308.6A patent/EP3849980B1/en active Active
- 2019-09-13 JP JP2021514073A patent/JP7731794B2/ja active Active
- 2019-09-13 CN CN201980060128.8A patent/CN112955449B/zh active Active
- 2019-09-13 MX MX2021002885A patent/MX2021002885A/es unknown
- 2019-09-13 AU AU2019338059A patent/AU2019338059B2/en active Active
- 2019-09-13 SG SG11202102497SA patent/SG11202102497SA/en unknown
- 2019-09-13 EP EP25161539.9A patent/EP4588919A1/en active Pending
-
2024
- 2024-10-09 US US18/910,093 patent/US20250034142A1/en active Pending
-
2025
- 2025-08-20 JP JP2025137091A patent/JP2025179092A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230081602A (ko) * | 2021-11-30 | 2023-06-07 | 주식회사 베노바이오 | Bet 단백질을 저해하는 신규한 카르복스아마이드 리독스 유도체 및 이를 이용한 안과질환 예방 및 치료용 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4588919A1 (en) | 2025-07-23 |
| US20250034142A1 (en) | 2025-01-30 |
| EP3849980B1 (en) | 2025-04-23 |
| EP3849980A1 (en) | 2021-07-21 |
| TW202024078A (zh) | 2020-07-01 |
| IL281258B1 (en) | 2025-11-01 |
| AU2019338059B2 (en) | 2025-03-20 |
| CN112955449A (zh) | 2021-06-11 |
| JP2022500433A (ja) | 2022-01-04 |
| WO2020053657A1 (en) | 2020-03-19 |
| US20220048905A1 (en) | 2022-02-17 |
| IL281258B2 (en) | 2026-03-01 |
| CA3111527A1 (en) | 2020-03-19 |
| MX2021002885A (es) | 2021-07-15 |
| TWI882964B (zh) | 2025-05-11 |
| SG11202102497SA (en) | 2021-04-29 |
| US12145932B2 (en) | 2024-11-19 |
| AU2019338059A1 (en) | 2021-04-01 |
| ES3034982T3 (en) | 2025-08-27 |
| JP7731794B2 (ja) | 2025-09-01 |
| JP2025179092A (ja) | 2025-12-09 |
| CN112955449B (zh) | 2025-04-29 |
| EA202190598A1 (ru) | 2021-08-02 |
| IL281258A (en) | 2021-04-29 |
| EP3849980A4 (en) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250034142A1 (en) | Method of manufacturing a solid form of a bet bromodomain inhibitor | |
| CN111386272B (zh) | 一种改进的瑞博西尼及其盐的制备方法 | |
| CN113227045B (zh) | 取代的杂环稠合的γ-咔啉的合成 | |
| TWI697494B (zh) | 科帕利普(copanlisib)及其二鹽酸鹽之合成 | |
| JP2013522327A (ja) | ラパチニブの調製プロセス及び中間体 | |
| JP2023011667A (ja) | スルホンアミド構造のキナーゼ阻害剤の製造方法 | |
| CN110891947A (zh) | 制备艾乐替尼或其药学上可接受的盐的方法 | |
| CN109384767B (zh) | 一种吡啶并嘧啶类衍生物的制备方法及其中间体 | |
| JP2022500433A5 (cg-RX-API-DMAC7.html) | ||
| EA043992B1 (ru) | Способ изготовления твердой формы ингибитора бромодомена bet | |
| JP2015038053A (ja) | 4−(2−メチル−1−イミダゾリル)−2,2−フェニルブタンアミドの製造方法 | |
| HK40053356A (en) | Method of manufacturing a solid form of a bet bromodomain inhibitor | |
| WO2016071382A1 (en) | Synthesis of pi3k inhibitor and salts thereof | |
| JP6997769B2 (ja) | 2-(6-ニトロピリジン-3-イル)-9H-ジピリド[2,3-b;3’,4’-d]ピロールの製造方法 | |
| EP4538259A1 (en) | Processes for the preparation of deucravacitinib | |
| HK40053356B (en) | Method of manufacturing a solid form of a bet bromodomain inhibitor | |
| EP3687987A1 (en) | Crystalline forms of lenalidomide | |
| HK40081621A (en) | Process for the preparation of a sulfonamide structured kinase inhibitor | |
| CN121293155A (zh) | 用于达罗他胺的中间体的制备方法 | |
| WO2020140957A1 (en) | Method for preparing sulfonamides drugs | |
| HK40021800A (en) | Process for the preparation of a sulfonamide structured kinase inhibitor | |
| HK40021800B (en) | Process for the preparation of a sulfonamide structured kinase inhibitor | |
| WO2016071380A1 (en) | Synthesis of pi3k inhibitor and salts thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| F13 | Ip right granted in full following pre-grant review |
Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |
|
| F13 | Ip right granted in full following pre-grant review |
Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |